{"id":10206,"date":"2026-07-15T08:22:51","date_gmt":"2026-07-15T06:22:51","guid":{"rendered":"https:\/\/cleanpeptides.eu\/nad-doseringsguide\/"},"modified":"2026-07-15T08:22:51","modified_gmt":"2026-07-15T06:22:51","slug":"nad-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/nad-doseringsguide\/","title":{"rendered":"NAD+ doseringsguide: IV, subkutant og orale forstadier"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><em>Nikotinamid-adenin-dinukleotid \u2014 IV-, subkutan- og orale forstadieprotokoller (NMN, NR) til levetid, energi og DNA-reparation. Kun til forskningsform\u00e5l \u2014 ikke til human brug.<\/em><\/p>\n<p class=\"wp-block-paragraph\">Clean Peptides giver ikke r\u00e5dgivning om dosering eller anvendelse. Denne guide samler produktinformation fra Clean Peptides sammen med uafh\u00e6ngigt undervisningsmateriale fra PeptideWiki, kun som forskningsreference. Det er ikke medicinsk r\u00e5dgivning og udg\u00f8r hverken anbefalinger, godkendelser eller instruktioner fra Clean Peptides.<\/p>\n<h2 class=\"wp-block-heading\">Hvad er NAD+?<\/h2>\n<p class=\"wp-block-paragraph\">NAD+ (nikotinamid-adenin-dinukleotid) er et coenzym, der findes i hver celle \u2014 essentielt for energiproduktion, DNA-reparation og genregulering. Det er en elektronb\u00e6rer i mitokondriel respiration, en n\u00f8dvendig kofaktor for sirtuiner (SIRT1\u20137, &#8220;levetidsenzymerne&#8221;) og et substrat for PARP-DNA-reparationsenzymer. Teknisk set et dinukleotid (ikke et peptid) er NAD+ centralt i levetidsmilj\u00f8et og kombineres rutinem\u00e6ssigt med peptider som MOTS-c, SS-31 og Epitalon. NAD+-niveauerne falder ~50 % mellem 40- og 60-\u00e5rsalderen.<\/p>\n<p class=\"wp-block-paragraph\">Doseringen stammer fra kliniske protokoller, publiceret forskning og erfaring fra f\u00e6llesskabet.<\/p>\n<h2 class=\"wp-block-heading\">N\u00f8gleegenskaber<\/h2>\n<ul class=\"wp-block-list\">\n<li>Centralt coenzym i cellul\u00e6r energioms\u00e6tning \u2014 essentielt for ATP-produktion.<\/li>\n<li>Sirtuin-kofaktor (SIRT1\u20137) \u2014 regulerer aldring, bet\u00e6ndelse, stressmodstand, DNA-reparation.<\/li>\n<li>PARP-substrat til DNA-reparation \u2014 et stort NAD+-dr\u00e6n, der stiger med alderen.<\/li>\n<li>CD38-relateret fald \u2014 CD38-aktiviteten stiger med alderen og forbruger NAD+.<\/li>\n<li>Flere strategier \u2014 IV, subkutant, orale forstadier (NMN, NR, niacin, niacinamid).<\/li>\n<li>~50 % fald mellem 40- og 60-\u00e5rsalderen.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">S\u00e5dan fastl\u00e6gges doseringen<\/h2>\n<p class=\"wp-block-paragraph\">Baseret p\u00e5 IV-klinikprotokoller, PK-fors\u00f8g med orale forstadier (NMN, NR), forskning i NAD+-metabolisme og erfaring fra f\u00e6llesskabet. NR ved 1000 mg\/dag h\u00e6ver NAD+ med 40\u201390 %; NMN ved 250 mg\/dag forbedrer insulinf\u00f8lsomheden i fors\u00f8g. IV-protokoller (250\u20131000 mg over 2\u20138 t) opstod i afh\u00e6ngighedsmedicinen. Evidensstyrke: st\u00e6rk for orale forstadier, moderat for injicerbar.<\/p>\n<h2 class=\"wp-block-heading\">Standarddoseringsintervaller<\/h2>\n<h3 class=\"wp-block-heading\">IV-infusion (klinisk)<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis\/session<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Infusionstid<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Start<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u20133 timer<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u00d7\/uge<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">3\u20134 timer<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u20132\u00d7\/uge<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8j \/ terapeutisk<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">750\u20131000 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4\u20138 timer<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Efter protokol<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">Subkutant<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis\/injektion<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Ugentligt total<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Start<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">50\u2013100 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u00d7\/uge<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013200 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013200 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u20133\u00d7\/uge<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u2013600 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jere interval<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Dagligt eller n\u00e6sten dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Op til 1000+ mg<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">Orale forstadier<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Forstadie<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Start<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Standard<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">H\u00f8jere interval<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">NMN<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1000 mg\/dag<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">NR (Niagen)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300\u2013600 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">600\u20131000 mg\/dag<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Niacin (NA)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">50 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013500 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1000+ mg\/dag<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Niacinamid (NAM)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1000 mg\/dag<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Sammenligning af administrationsveje<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Parameter<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">IV-infusion<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Subkutant<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Orale forstadier<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Typisk dosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250\u20131000 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013200 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250\u20131000 mg\/dag<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">NAD+-stigning<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jeste akutte spids<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Betydelig<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Moderat, vedvarende<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Pris<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250\u20131000+ $\/session<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013300 $\/m\u00e5ned<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">30\u2013100 $\/m\u00e5ned<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Bedst til<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Akut opladning, afh\u00e6ngighed, neuro<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Langsigtet daglig levetid<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Evidens<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Klinisk praksis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Klinisk praksis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Flere humane fors\u00f8g<\/td>\n<\/tr>\n<\/table>\n<p class=\"wp-block-paragraph\">&#8220;Oplad og vedligehold&#8221;: IV-opladning (2\u20134 sessioner over 1\u20132 uger) og derefter SubQ (2\u20133\u00d7\/uge) og\/eller daglige orale forstadier.<\/p>\n<h3 class=\"wp-block-heading\">Orale forstadier: NMN vs NR<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Egenskab<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">NMN<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">NR (Niagen)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Vej<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">\u00c9t trin f\u00f8r NAD+<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">To trin f\u00f8r NAD+<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standarddosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">250\u20131000 mg\/dag<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">300\u2013600 mg\/dag<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Kliniske fors\u00f8g<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Flere (stigende)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Flere publicerede fors\u00f8g<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Regulatorisk (USA)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Omstridt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">FDA-anerkendt som GRAS<\/td>\n<\/tr>\n<\/table>\n<p class=\"wp-block-paragraph\">Begge virker og t\u00e5les godt. Regelm\u00e6ssigheden af daglig brug betyder mere end hvilket forstadie man v\u00e6lger.<\/p>\n<h2 class=\"wp-block-heading\">Rekonstituering og dosering (med de medf\u00f8lgende 3 mL)<\/h2>\n<p class=\"wp-block-paragraph\">Clean Peptides NAD+-h\u00e6tteglasset er p\u00e5 1000 mg. Rekonstitueret i 3 mL er det meget koncentreret (333,33 mg\/mL); mange forskere fortynder i stedet NAD+ i et st\u00f8rre volumen til IV-brug. Tallene nedenfor er for subkutan dosering fra de medf\u00f8lgende 3 mL.<\/p>\n<p class=\"wp-block-paragraph\">Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Hurtig formel:<\/strong> koncentration = h\u00e6tteglasstyrke \u00f7 3 mL, og enheder at tr\u00e6kke op = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglasstyrke (mg).<\/p>\n<h3 class=\"wp-block-heading\">S\u00e5dan rekonstitueres<\/h3>\n<ol class=\"wp-block-list\">\n<li>Vask h\u00e6nderne og l\u00e6g h\u00e6tteglasset, de 3 mL bakteriostatisk vand, en insulinspr\u00f8jte og spritservietter frem p\u00e5 en ren overflade.<\/li>\n<li>Vip h\u00e6tterne af og aft\u00f8r begge gummipropper med sprit; lad dem luftt\u00f8rre 10\u201315 sekunder.<\/li>\n<li>Tr\u00e6k de fulde 3 mL bakteriostatisk vand op (i tre 1 mL-omgange med en insulinspr\u00f8jte eller i \u00e9n omgang med en 3 mL-spr\u00f8jte).<\/li>\n<li>Tils\u00e6t vandet langsomt, og vinkl n\u00e5len, s\u00e5 det l\u00f8ber ned ad den indvendige glasv\u00e6g \u2014 spr\u00f8jt det aldrig direkte p\u00e5 pulveret.<\/li>\n<li>Opl\u00f8s forsigtigt \u2014 lad h\u00e6tteglasset st\u00e5 1\u20132 minutter, og hvirvl eller rul det derefter mellem h\u00e5ndfladerne, til opl\u00f8sningen er klar. Ryst aldrig.<\/li>\n<li>M\u00e6rk og opbevar i k\u00f8leskab ved 2\u20138 \u00b0C. Resulterende koncentration: 1000 mg \u2192 333,33 mg\/mL.<\/li>\n<\/ol>\n<p class=\"wp-block-paragraph\"><strong>Opbevaring:<\/strong> ikke-rekonstitueret pulver i k\u00f8leskab (2\u20138 \u00b0C); rekonstitueret opl\u00f8sning i k\u00f8leskab og anvendt inden for 28\u201330 dage; m\u00e5 ikke fryses; beskyt mod lys og varme.<\/p>\n<h3 class=\"wp-block-heading\">Optr\u00e6ksvolumener med 3 mL \u2014 NAD+<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Koncentration<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">50 mg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">100 mg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">200 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">1000 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">333,33 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">15 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">30 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">60 e<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Dosering efter m\u00e5l<\/h2>\n<ul class=\"wp-block-list\">\n<li><strong>Generel levetid og anti-aging:<\/strong> oral NMN 500 mg\/dag eller NR 300\u2013600 mg\/dag, om morgenen; + TMG 500\u20131000 mg\/dag. Kombin\u00e9r med Epitalon, MOTS-c.<\/li>\n<li><strong>Energi og mitokondriel optimering:<\/strong> oral NMN 500\u20131000 mg\/dag \u00b1 SubQ 100\u2013200 mg 2\u00d7\/uge; + MOTS-c, SS-31.<\/li>\n<li><strong>Kognition og neurobeskyttelse:<\/strong> IV 500 mg (2\u20134 opladningssessioner) + vedligeholdelse med oral NMN 500\u20131000 mg\/dag.<\/li>\n<li><strong>Afh\u00e6ngighedsbehandling:<\/strong> IV 500\u20131000 mg\/session dagligt 7\u201314 dage (kun p\u00e5 l\u00e6geklinik).<\/li>\n<li><strong>DNA-reparation og genomisk integritet:<\/strong> oral NMN 500\u20131000 mg\/dag + SubQ 100 mg 2\u20133\u00d7\/uge; + Epitalon, SS-31.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Tilpas intensiteten til m\u00e5let \u2014 de fleste f\u00e5r mest ud af konsekvent daglig oral NMN eller NR.<\/p>\n<h2 class=\"wp-block-heading\">Cyklus og varighed<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Protokol<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Varighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Cyklus<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Oral NMN\/NR (vedligeholdelse)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">L\u00f8bende (ubegr\u00e6nset)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Ingen cyklus n\u00f8dvendig<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">SubQ NAD+ (vedligeholdelse)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">L\u00f8bende eller periodisk<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Valgfrit 8 ugers brug \/ 4 ugers pause<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">IV NAD+ (opladning)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u20132 uger (2\u20134 sessioner)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Overgang til SubQ\/oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">IV NAD+ (terapeutisk)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">7\u201314 sammenh\u00e6ngende dage<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Efter klinisk protokol<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Periodiske IV-boostere<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1 session hver 4.\u20138. uge<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Sammen med daglig oral<\/td>\n<\/tr>\n<\/table>\n<p class=\"wp-block-paragraph\">NAD+ er en metabolisk kofaktor, ikke en receptoragonist \u2014 ingen desensibilisering; kontinuerlig daglig oral brug er standard.<\/p>\n<h2 class=\"wp-block-heading\">Kombinationsprotokoller<\/h2>\n<ul class=\"wp-block-list\">\n<li>NAD+ + MOTS-c \u2014 mitokondriel optimering (ETC-br\u00e6ndstof + AMPK-aktivering).<\/li>\n<li>NAD+ + SS-31 \u2014 mitokondriel membranintegritet (cardiolipin-stabilisering).<\/li>\n<li>NAD+ + Epitalon \u2014 levetid og telomervedligeholdelse.<\/li>\n<li>NAD+ + metformin \u2014 adskil doseringen med flere timer (mulig interferens med tr\u00e6ningsfordele).<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">NAD+ er grundl\u00e6ggende, ikke overfl\u00f8digt \u2014 det giver br\u00e6ndstof til de veje, disse peptider retter sig mod. Fulde MOTS-c-protokoller: se vores <a href=\"https:\/\/cleanpeptides.eu\/da\/mots-c-doseringsguide\/\">MOTS-c-doseringsguide<\/a>.<\/p>\n<h2 class=\"wp-block-heading\">Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p class=\"wp-block-paragraph\">Orale forstadier har fremragende sikkerhedsprofiler; IV\/SC har mere akutte effekter.<\/p>\n<p class=\"wp-block-paragraph\"><strong>IV (hastighedsafh\u00e6ngig):<\/strong> r\u00f8dmen, trykken\/tryk for brystet, kvalme\/kramper, angst, hovedpine, svimmelhed \u2014 alt forsvinder, n\u00e5r infusionen s\u00e6nkes. <strong>SC:<\/strong> svien\/br\u00e6nden ved injektionsstedet, r\u00f8dme, let r\u00f8dmen. <strong>Oral (NMN\/NR):<\/strong> meget milde; sj\u00e6lden GI-uro; mulig s\u00f8vnforstyrrelse hvis taget sent. Niacin specifikt giver r\u00f8dmen over 50\u2013100 mg.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Kontraindikationer:<\/strong> aktiv kr\u00e6ft (dr\u00f8ft med onkolog); graviditet\/amning (undg\u00e5 injicerbar); bl\u00f8dningsforstyrrelser\/antikoagulantia; leversygdom (risiko ved h\u00f8jdosis-niacin \u2014 NMN\/NR deler ikke denne risiko).<\/p>\n<h2 class=\"wp-block-heading\">Almindelige fejl<\/h2>\n<ul class=\"wp-block-list\">\n<li>At k\u00f8re IV-infusionen for hurtigt (hoved\u00e5rsag til sv\u00e6re bivirkninger).<\/li>\n<li>At forvente, at oral NAD+ (molekylet) virker som NMN\/NR (d\u00e5rlig biotilg\u00e6ngelighed \u2014 brug forstadier).<\/li>\n<li>Uregelm\u00e6ssig daglig forstadiedosering.<\/li>\n<li>At ignorere kr\u00e6ftbekymringen hos h\u00f8jrisikopersoner.<\/li>\n<li>At springe methyldonorst\u00f8tte (TMG) over ved h\u00f8jdosisbrug.<\/li>\n<li>At v\u00e6lge den dyreste vej uden at matche m\u00e5l.<\/li>\n<li>Forkert opbevaring efter rekonstituering.<\/li>\n<li>At tage NMN\/NR om aftenen (s\u00f8vnforstyrrelse \u2014 tag om morgenen).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Hovedpunkter<\/h2>\n<ul class=\"wp-block-list\">\n<li>Centralt coenzym for energi, DNA-reparation og aldring; falder ~50 % mellem 40- og 60-\u00e5rsalderen.<\/li>\n<li>Teknisk set ikke et peptid, men bredt anvendt i levetids-\/peptidmilj\u00f8et.<\/li>\n<li>Veje: IV (h\u00f8jest, dyrest), SubQ (moderat, hjemmebrug), oral NMN\/NR (mest praktisk dagligt).<\/li>\n<li>Orale forstadier er grundstammen: NMN 500 mg\/dag eller NR 300\u2013600 mg\/dag + TMG.<\/li>\n<li>SubQ NAD+ svier, men t\u00e5les godt (100\u2013200 mg, 2\u20133\u00d7\/uge). Bedste kombinationer: MOTS-c, SS-31, Epitalon.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Referencer<\/h2>\n<ol class=\"wp-block-list\">\n<li>Camacho-Pereira J, et al. &#8220;CD38 dictates age-related NAD decline.&#8221; Cell Metab. 2016;23(6):1127-1139.<\/li>\n<li>Yoshino J, et al. &#8220;NAD+ intermediates: NMN and NR.&#8221; Cell Metab. 2018;27(3):513-528.<\/li>\n<li>Martens CR, et al. &#8220;Chronic NR supplementation elevates NAD+ in older adults.&#8221; Nat Commun. 2018;9(1):1286.<\/li>\n<li>Yoshino M, et al. &#8220;NMN increases muscle insulin sensitivity in prediabetic women.&#8221; Science. 2021;372(6547):1224-1229.<\/li>\n<li>Rajman L, et al. &#8220;Therapeutic potential of NAD-boosting molecules.&#8221; Cell Metab. 2018;27(3):529-547.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Download og relaterede ressourcer<\/h2>\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/12-NAD-Dosage-Guide-Clean-Peptides.pdf\" target=\"_blank\" rel=\"noopener\">\ud83d\udcc4 Download den fulde PDF-guide<\/a><\/p>\n<p class=\"wp-block-paragraph\">K\u00f8b NAD+: <a href=\"https:\/\/cleanpeptides.eu\/product\/nad-1000-mg\/\">NAD+ 1000 mg<\/a><\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Nikotinamid-adenin-dinukleotid \u2014 IV-, subkutan- og orale forstadieprotokoller (NMN, NR) til levetid, energi og DNA-reparation. Kun til forskningsform\u00e5l \u2014 ikke til [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10206","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10206"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10206\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}